Rachel Vaknin - Microbot Medical Chief Officer

Microbot Medical Management Efficiency

The company has return on total asset (ROA) of (0.6488) % which means that it has lost $0.6488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3446) %, meaning that it created substantial loss on money invested by shareholders. Microbot Medical's management efficiency ratios could be used to measure how well Microbot Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.23 in 2024. Return On Capital Employed is likely to gain to -2.06 in 2024. Total Current Liabilities is likely to gain to about 4.8 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 7.9 M in 2024.

Similar Executives

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts. Microbot Medical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. Microbot Medical (MBOT) is traded on NASDAQ Exchange in USA. It is located in 288 Grove Street, Braintree, MA, United States, 02184 and employs 21 people. Microbot Medical is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Microbot Medical Leadership Team

Microbot Stock Performance Indicators

Additional Tools for Microbot Stock Analysis